Dr. Reddy's North America Revenue Expected to Trough — Market Talk

Dr. Reddy's Laboratories' North America revenue is expected to trough this fiscal year, supported by the potential U.S. launch of abatacept biosimilar and the resumption of semaglutide supplies in Canada, Citi Research's Vivek Agrawal says in a note. At the same time, improving growth in India, oth…